Potentiation of BKCa channels by cystic fibrosis transmembrane conductance regulator correctors VX-445 and VX-121
Authors:
Open Access
- 2 July 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (16)
Abstract
Cystic fibrosis results from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) anion channel, ultimately leading to diminished transepithelial anion secretion and mucociliary clearance. CFTR correctors are therapeutics that restore the folding/trafficking of mutated CFTR to the plasma membrane. The large-conductance calcium-activated potassium channel (BK Ca , K Ca 1.1) is also critical for maintaining lung airway surface liquid (ASL) volume. Here, we show that the class 2 (C2) CFTR corrector VX-445 (elexacaftor) induces K + secretion across WT and F508del CFTR primary human bronchial epithelial cells (HBEs), which was entirely inhibited by the BK Ca antagonist paxilline. Similar results were observed with VX-121, a corrector under clinical evaluation. Whole-cell patch-clamp recordings verified that CFTR correctors potentiated BK Ca activity from both primary HBEs and HEK cells stably expressing the α subunit (HEK-BK cells). Furthermore, excised patch-clamp recordings from HEK-BK cells verified direct action on the channel and demonstrated a significant increase in open probability. In mouse mesenteric artery, VX-445 induced a paxilline-sensitive vasorelaxation of preconstricted arteries. VX-445 also reduced firing frequency in primary rat hippocampal and cortical neurons. We raise the possibilities that C2 CFTR correctors gain additional clinical benefit by activation of BK Ca in the lung yet may lead to adverse events through BK Ca activation elsewhere.Keywords
Funding Information
- Cystic Fibrosis Foundation (DEVOR22GO,DEVOR23GO)
- Cystic Fibrosis Foundation (BRIDGE18XXO)
- Cystic Fibrosis Foundation (CFF RDP)
- Norges Idrettshøgskole (DK102843)
- Norges Idrettshøgskole (R35 HL161177)
- Norges Idrettshøgskole (R56RAG058593)
This publication has 96 references indexed in Scilit:
- Understanding CFTR Functionality: A Comprehensive Review of Tests and Modulator Therapy in Cystic FibrosisCell Biochemistry and Biophysics, 2023
- Cystic FibrosisJAMA, 2023
- Management of neuropsychiatric symptoms in adults treated with elexacaftor/tezacaftor/ivacaftorPediatric Pulmonology, 2023
- Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic ImpairmentEuropean Journal of Drug Metabolism and Pharmacokinetics, 2022
- Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19Clinical Pharmacology & Therapeutics, 2022
- Targeting BKCa Channels in Migraine: Rationale and PerspectivesCNS Drugs, 2020
- Use of Primary Cultures of Human Bronchial Epithelial Cells Isolated from Cystic Fibrosis Patients for the Pre-clinical Testing of CFTR Modulators2011
- Multiple KCNQ Potassium Channel Subtypes Mediate Basal Anion Secretion from the Human Airway Epithelial Cell Line Calu-3The Journal of Membrane Biology, 2008
- Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channelCell, 1991
- Calcium: A program in basic for calculating the composition of solutions with specified free concentrations of calcium, magnesium and other divalent cationsComputers in Biology and Medicine, 1988